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viral rebound after ART discontinuing.[1–3] 
Recent studies demonstrated that viral 
reservoirs were seeded within 1–3 days 
of infection in the simian immunode-
ficiency virus (SIV) model of acquired 
immune deficiency syndrome (AIDS), 
and therefore even early ART treatment 
after 3 days of infection cannot block the 
establishment of persistent infection.[4–6] 
Alternatively, several strategies including 
shock-and-kill, chimeric antigen receptor 
T-cell therapy, therapeutic vaccination, and 
gene editing[7–12] are extensively explored 
to target the latent reservoir.
It is therefore of great interest to 
develop novel strategies to render latent 
proviruses susceptible to eradication. 
Among them, reactivation of latent provi-
ruses with latency-reversing agents (LRA) 
is critical for the efficacy of shock-and-kill 
strategy. An ideal LRA should activate the 
latent proviruses without extensive T cell 
activation and inflammatory responses. 
Various compounds, including chromatin 
remodeling agents such as histone dea-
cetylase acetylation inhibitors (suberoylanilide hydroxamic 
acid (SAHA) and valproic acid (VPA)) or T cell activators (bry-
ostatin-1), have been tested as potential LRA to “shock out” 
the latent proviruses in preclinical and clinical studies.[13–16] 
The latent viral reservoir is the source of viral rebound after interruption of 
antiretroviral therapy (ART) and is the major obstacle in eradicating the latent 
human immunodeficiency virus-1 (HIV-1). In this study, arsenic class of 
mineral, arsenic trioxide, clinically approved for treating acute promyelocytic 
leukemia, is demonstrated to reactivate latent provirus in CD4+ T cells from 
HIV-1 patients and Simian immunodeficiency virus (SIV)-infected macaques, 
without significant systemic T cell activation and inflammatory responses. 
In a proof-of-concept study using chronically SIVmac239-infected macaques, 
arsenic trioxide combined with ART delays viral rebound after ART termina-
tion, reduces the integrated SIV DNA copies in CD4+ T cells, and restores 
CD4+ T cells counts in vivo. Most importantly, half of arsenic trioxide-treated 
macaques show no detectable viral rebound in the plasma for at least 80 days 
after ART discontinuation. Mechanistically, the study reveals that CD4 recep-
tors and CCR5 co-receptors of CD4+ T cells are significantly downregulated by 
arsenic trioxide treatment, which reduces susceptibility to infection after pro-
virus reactivation. Furthermore, an increase in SIV-specific immune responses 
after arsenic trioxide treatment may contribute to suppression of viral 
rebound. This work suggests that arsenic trioxide in combination with ART is 
a novel regimen in down-sizing or even eradicating latent HIV-1 reservoir.
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Antiretroviral therapy (ART) results in effective control of 
human immunodeficiency virus-1 (HIV-1) replication in 
plasma to undetectable levels, but fails to eradicate latent viral 
reservoir, which has been recognized as the major source of 
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However, a safe and effective LRA has so far not been identified 
for clinical use.
Arsenic class of mineral has long history of being used in 
medical practice. In traditional Chinese medicine, it is well known 
as “Pi-Shuang” in the treatment of tuberculosis and parasitic 
infections in ancient China, which was documented in Shennong 
Bencao Jing (Shennong Emperor’s Classic of Materia Medica) 
in the 1st century AD. In modern medicine, an arsenical drug, 
arsenic trioxide (As2O3), has been approved for the treatment of 
acute promyelocytic leukemia (APL) and hepatocellular carcinoma 
(HCC) in clinic.[17–19] Several studies demonstrated that arsenic 
trioxide can react with cysteine residues and elicit critical tran-
scription signal factors, including protein kinase C, NF-kB, pro-
myelocytic leukemia nuclear body (PML-NB), mitogen-activated 
protein kinases, and retinoic acid receptor alpha.[20,21] Arsenic can 
also irreversibly inhibit mammalian thioredoxin reductase which 
is one of the electron donor systems that control cellular prolifera-
tion, viability, and apoptosis through elevated oxidative stress.[22] 
Since these transcription factors and signal pathways were 
reported to affect HIV-1 latency, arsenic trioxide might also modu-
late HIV-1 reservoir. For example, arsenic trioxide was reported to 
degrade PML-NB suppressor by sumoylation and thereby reverse 
the inhibition of transcription, and the silenced but transcription-
ally competent HIV-1 proviruses usually reside in close proximity 
to PML-NB in CD4+ T cells.[23] Indeed, previous studies have 
shown that arsenic trioxide enhanced retroviral reverse transcrip-
tion of HIV-1[24] and induced activation of latent HIV-1 in Jurkat 
T cell line.[23,25] Furthermore, sodium arsenite reactivated gene 
expression and virus replication from the latency genome of 
herpes simplex virus type 1 in vitro.[26] Nevertheless, there is no 
evidence whether the latent HIV/SIV reservoir can be targeted fol-
lowing arsenic trioxide administration in vivo.
Collectively, these studies inspired us to explore arsenic tri-
oxide in combination with ART as a novel regimen to target 
the viral reservoir for HIV-1 functional cure. In this study, we 
therefore investigated how viral reservoir could be regulated by 
arsenic trioxide in primary CD4+ T lymphocytes and in SIV-
infected, ART-treated Chinese rhesus macaques.
The first objective of this study was to find out whether 
arsenic trioxide has any effects on the latent provirus, and we 
found that arsenic trioxide induced HIV-1 reactivation in a dose-
dependent manner in Jurkat-Lat HIV-1 full length clone A10.6 
cells (Figure 1A,B). After 24 h treatment with different concen-
trations of arsenic trioxide, the percentage of green fluorescent 
protein (GFP)-expressing cells, which represents the transcrip-
tional activated HIV-1, increased from 2.8% to 13.2%, when the 
concentration of arsenic trioxide increased from 125 × 10−9 to 
10 × 10−6 m (Figure 1B). A histone deacetylase inhibitor VPA 
(5 × 10−3 m) upregulated GFP-expressing cells to 26.7%, and 
was enhanced to 56% with added 1.25 × 10−6 m arsenic trioxide 
Adv. Sci. 2019, 1900319
Figure 1. Arsenic trioxide reactivated latent provirus in J-Lat HIV latency cell line, primary CD4+ T cells from HIV-1 patient, and SIVmac239-infected 
macaques. A) J-Lat A10.6 cells were treated with arsenic trioxide or VPA. At 24 h post-treatment, the percentage of GFP-positive cells was analyzed by 
flow cytometry. GFP expression represents the transcriptional activity of HIV-1 promoter. VPA was used as a positive control for provirus reactivation. 
B) Dose-dependent reactivation of HIV-1 latency by arsenic trioxide in J-Lat A10.6 cells. C) Synergistic activation of HIV-1 latency by arsenic trioxide 
with VPA in J-Lat A10.6 cells. The cell-associated RNA (CA- RNA) expression in primary CD4+ T cells from SIV-infected rhesus macaques and HIV-
1-infected patients were measured as our previously reported.[29] The numbers of D) SIV msRNA, E) SIV usRNA, and F) HIV-1 msRNA, G) HIV-1 
usRNA per million of CD4+ T cells were determined by nested PCR. Data were presented as the mean ± standard deviation of triplicate experiments. 
SSC: Side Scatter; GFP: green fluorescent protein; VPA: valproic acid; RM: Rhesus Macaques; msRNA: multiply spliced RNA; usRNA: unspliced RNA.
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(Figure 1C). This demonstrated that arsenic trioxide syner-
gistically reactivated latent HIV-1 when combined with VPA 
(Figure 1A–C).
Although Jurkat-Lat T cell line is a commonly used model 
to mimic HIV-1 latency, it may not reflect the genetic diver-
sity of viral reservoir pool of primary cells, in which HIV pro-
viruses are integrated into different sites in the host genome. 
Hence, we used primary CD4+ T cells from SIV-infected rhesus 
macaques and HIV-1-infected patients, to further evaluate reac-
tivation efficacy of arsenic trioxide.
SIV-infected macaques used in this study had a history 
of SIVmac239 infection for more than 5 years as previously 
reported,[27,28] and had several courses of ART therapy to con-
trol viral load in plasma to undetectable levels (Table S1, Sup-
porting Information). In addition, CD4+ T cells were obtained 
from four HIV-1 patients who received prolonged ART therapy 
and achieved an effective control of viral replication in plasma 
(Table S2, Supporting Information). Purified CD4+ T cells were 
incubated with arsenic trioxide. Cell-associated SIV or HIV-1 
RNA in arsenic trioxide-treated CD4+ T lymphocytes isolated 
from SIV-infected macaques or HIV-1 patients was detected as 
previously reported.[29] Cell-associated RNA in peripheral blood 
mononuclear cells (PBMC), such as multiply spliced RNA 
(msRNA) and unspliced RNA (usRNA), was associated with 
HIV replication and disease progression, and was thought to 
be a sensitive parameter to represent the status of viral tran-
scription and reactivation. Notably, the level of msRNA and 
usRNA copies in resting CD4+ T cells from both SIV-infected 
macaques (Figure 1D,E) and HIV-1 patients (Figure 1F,G) were 
significantly induced with arsenic trioxide in a dose-dependent 
manner. These data demonstrated that arsenic trioxide can 
activate HIV-1 or SIV transcription in primary CD4+ T cells. To 
evaluate if arsenic trioxide exerts cell cytotoxicity, viability was 
assessed in primary PBMCs, treated with increasing concentra-
tions of arsenic trioxide. There were no significant effects on 
cell viability at concentration as high as 10 × 10−6 m, but the tox-
icity became obvious at 20 × 10−6 m and higher concentrations 
(Figure S1, Supporting Information).
We next investigated the effect of arsenic trioxide on T cell 
activation, proliferation and inflammation. PBMCs from SIV-
infected macaques were treated with arsenic trioxide (1.25 × 
10−6–12.5 × 10−6 m) for 24 h. The expression of CD25, CD38, 
CD69, and HLA-DR on PBMCs was determined by flow cytom-
etry. A cocktail of phorbol 12-myristate 13-acetate (PMA) and 
ionomycin was used as a positive control for T cell activation 
and proliferation. There was no significant increase in CD25, 
CD69, or HLA-DR and CD38 expression in CD4+ T and CD8+ 
T cells treated with arsenic trioxide for 24 h at concentrations 
up to 12.5 × 10−6 m (Figure 2A–F), unlike those with the PMA 
stimulation. In addition, there was no significant increase in 
the proliferative responses of CD4+ T and CD8+ T cells with 
arsenic trioxide treatment, tested by staining with carboxy-
fluorescein succinimidyl ester (CFSE) (Figure 2G,H). Similar 
results were also found when CD4+ T and CD8+ T cells were 
incubated with arsenic trioxide for 5 days at 12.5 × 10−6 m 
(Figure S2, Supporting Information).
Proinflammatory responses, characterized by the produc-
tion of inflammatory cytokines, such as interleukin (IL)-1β, 
IL-6, IL-8, tumor necrosis factor alpha (TNF-α), and  inter-
feron (IFN)-γ, are often increased by traditional LRA treat-
ment. We therefore investigated the effects of arsenic tri-
oxide on the inflammatory responses. Although IL-1β and 
Adv. Sci. 2019, 1900319
Figure 2. Effects of arsenic trioxide on T cell activation and proliferation. PBMCs from Chinese rhesus macaques were treated with arsenic trioxide for 24 h. 
A–F) The expressions of T cell activation markers were detected by flow cytometry, including CD25+, CD69+, and CD38+/HLA-DR+ on the surface of CD8+ 
T and CD4+ T cells from SIV-infected macaques. The proliferative responses of G) CD4+ T and H) CD8+ T cells after arsenic trioxide treatment were deter-
mined by carboxyfluorescein succinimidyl ester (CFSE) staining. PMA and ionomycin were used as positive controls for T cell activation and proliferation.
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IL-6 were induced, IL-8 and IFN-γ were not elicited when 
PBMCs were treated with arsenic trioxide up to 12.5 × 10−6 m  
(Figure 3A). TNF-α was increased only at the higher concen-
tration of arsenic trioxide of 12.5 × 10−6 m, which might be 
related to the arsenic trioxide-induced cell apoptosis. Next, 
we used lipopolysaccharide (LPS) to stimulate freshly isolated 
PBMC cells to further investigate the effects of arsenic tri-
oxide on the inflammatory responses. Interestingly, arsenic 
trioxide appeared to suppress the LPS-induced expression 
of IL-1β, IL-6, IL-8, and IFN-γ (Figure 3B). Taken together, 
arsenic trioxide can reactivate latent proviruses without sig-
nificantly devastating T cell activation and proinflammatory 
responses.
We then assessed the potential therapeutic effects of admin-
istering arsenic trioxide in chronically SIVmac239-infected, 
ART-treated rhesus macaques (Figure 4A). The arsenic tri-
oxide formulation used in this study was a clinically available 
drug NAWEIYA, which has been approved for the treatment 
of acute promyelocytic leukemia and hepatocellular carci-
noma in China. A cohort of chronically SIVmac239-infected 
rhesus macaques was divided into two comparable groups 
according to viral load, weight, and age (Table S1, Supporting 
Information). One group of macaques received ART alone 
and another group received in addition intravenous injections 
of 0.16 mg kg−1 arsenic trioxide, which is the same dosage 
as that clinically used to treat APL patients. All macaques 
have been infected with SIVmac239 for more than 5 years 
and had persistent viral infection.[28,29] They have previously 
received several courses of ART (30 mg kg−1 (R)-9-(2-phosph-
onylmethoxypropyl) adenine (PMPA) and 20 mg kg−1 beta-
2,3-dideoxy-3-thia-5-fluorocytidine (FTC)). Plasma viral loads 
in these macaques dropped below the detection limit during 
ART administration, but rebound quickly after stopping ART 
(Table S1, Supporting Information). Consistent with our pre-
vious observation, the SIV RNA copies rebounded in all of 
ART alone–treated macaques in an average interval of 22 days 
following discontinuation of ART (Figure 4C). Importantly, 
arsenic trioxide in combination with ART therapy delayed 
virus rebound after ART discontinuation.
Especially, two macaques showed no detectable virus in 
the plasma for at least 80 days after ART discontinuation 
(Figure 4B). Although no significant viral blips were observed in 
those monkeys, a significant decrease of integrated SIV provirus 
was found in CD4+ T lymphocytes in group of arsenic trioxide 
in combination with ART therapy, when compared with ART 
alone (Figure 4D, p < 0.05). In addition, the CD4+ T lymphocyte 
count was significantly restored in macaques with arsenic tri-
oxide administration, but not in the ART alone group (Figure 4E, 
p < 0.05). These findings suggest that arsenic trioxide in combi-
nation with ART therapy resulted in reducing the SIV reservoirs, 
restoring the immune reconstitution in chronically SIV-infected 
macaques, and delaying viral rebound after ART discontinuation.
We further explored the mechanism of arsenic trioxide in 
delaying viral rebound after ART discontinuation. Primary T 
cells isolated from SIV-infected or SIV-uninfected macaques 
were treated with arsenic trioxide, and results showed that 
although there was no significant change of the proportion 
of CD4+ T cells (Figure 5A), the expression level of CD4 and 
CCR5 on arsenic trioxide-treated CD4+ T cells was signifi-
cantly downregulated in a dose-dependent manner with arsenic 
trioxide treatment (p < 0.001, Figure 5B,C). In contrast, the 
proportion and expression level of CD8 and CCR5 on CD8+ T 
cells showed no significant change when treated with arsenic 
trioxide (Figure S3, Supporting Information).
Since CD4 receptors and CCR5 coreceptors are critical for 
HIV/SIV attachment and entry into target cells, these results 
suggest that arsenic trioxide might reduce the susceptibility of 
CD4+ T cells to viral infection during reactivation of latency 
provirus. To this end, primary CD4+ T cells with productive 
virions from SIV-infected rhesus macaques were incubated with 
different concentrations of arsenic trioxide for 62 h. The level of 
SIV viral copies in the intracellular extracts and in the culture 
media of primary CD4+ T cells were then measured. Compared 
with the mock-treated samples, a dose-dependent increase in 
Adv. Sci. 2019, 1900319
Figure 3. Inflammatory responses after arsenic trioxide treatment. A) PBMCs were treated with arsenic trioxide at the given concentrations for 24 h 
with or without ART drugs. The expression of the inflammatory cytokines was measured by quantitative RT-PCR analysis. B) PBMCs in the presence 
of LPS (5 µg L−1) were treated with arsenic trioxide at the given concentrations for 24 h with or without ART drugs; ART containing FTC(3 mg L−1) and 
PMPA(2 mg L−1); β-macroglobulin was used as the internal control. Data are the means ± standard deviations from three independent experiments.
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Figure 4. Arsenic trioxide in combination with ART delayed viral rebound in SIV-infected rhesus macaques. A) Experimental schedule of proof-of-concept 
for functional cure by administration of arsenic trioxide combined with ART in chronic SIV-infected macaques. Eight Chinese rhesus macaques were 
divided into two groups according to viral load, weight, and age. One group received ART therapy alone (n = 4), and another group received intravenous 
injections of arsenic trioxide during ART therapy (n = 4). B) The viral loads for each experimental macaque in ART+arsenic trioxide groups were monitored 
overtime by real-time PCR; the sensitivity of this assay was 100 copies mL−1 plasma. C) The viral load for each experimental macaque in ART-only groups 
was monitored as above. The bold horizontal line in (B) and (C) represents the time of viral rebound after ART was discontinued. D) Alu-PCR analysis 
of the integrated SIV provirus copies in CD4+ T cells before and after ART with or without combination of arsenic trioxide. E) Numbers of circulating 
CD4+ T lymphocytes before and after ART with or without combination of arsenic trioxide. Cells were determined using BD TruCount tubes. * p < 0.05.
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SIV RNA copies (Figure 5D) and SIV DNA copies (Figure 5E) 
in CD4+ T cells was found after arsenic trioxide treatment. 
This was consistent with previous data (Figure 1D,E). How-
ever, a dose-dependent decrease in viral copies in the culture 
media of primary CD4+ T cells was found with the arsenic 
trioxide-treated samples, and undetectable viral copies with 
12.5 × 10−6 m of arsenic trioxide ((Figure 5F, p < 0.001). These 
findings suggest that arsenic trioxide suppressed SIV spread 
during reactivation of latent SIV provirus by downregulating 
the expression of viral CD4 receptors and CCR5 coreceptors.
Finally, we examined the effect of arsenic trioxide on T 
cell responses in chronically SIV-infected Chinese rhesus 
macaques. Specific T cell responses against SIV Gag, Pol, 
and Env antigens, expressed as IFN-γ-mediated enzyme-
linked immunosorbent spot (ELISPOT) responses, were 
found in all chronic SIV-infected Chinese rhesus macaques 
(Figure 6A,B). SIV-specific T cell responses were significantly 
increased after treatment with arsenic trioxide in combination 
with ART (Figure 6C). In comparison, SIV antigen-specific T 
cell responses were relatively unchanged in ART-only treated 
macaques (Figure 6C). Importantly, in vivo administration of 
arsenic trioxide in chronic SIV-infected macaques significantly 
downregulated the expression of CCR5 coreceptors, with no sig-
nificant change of expression in CD95 and CD69 T cell activa-
tion markers in CD4+ T cells (Figure 6D), which was consistent 
with the in vitro data (Figure 5). Taken together, these results 
suggest that arsenic trioxide in combination with ART may 
regulate antiviral T cell immune responses without devastating 
systemic T cell activation. The increased SIV-specific immune 
responses can eliminate the infected cells harboring latent SIV 
during the viral reactivation, and thus contribute to suppres-
sion of viral rebound in chronic SIV-infected rhesus macaques.
In the present study, we found that arsenic class of mineral, 
arsenic trioxide, a drug for the clinical treatment of APL and 
HCC, can reactivate the latent viral reservoir in vitro and in vivo. 
The therapeutic effect of arsenic trioxide was explored for the 
first time in a model of chronically SIV-infected macaques. In 
combination with ART, arsenic trioxide can significantly reduce 
the viral reservoirs and delay viral rebound after ART termina-
tion in this macaque model. Based on our current results, the 
likely mechanism for delaying viral rebound by this regiment 
may involve with at least three actions, including perturbation 
of viral reservoir, downregulation of CD4 primary receptors and 
CCR5 coreceptors for SIV entry on CD4+ T cells, and enhance-
ment of SIV specific immune responses.
As a prerequisite for HIV functional cure, we first verified 
how arsenic trioxide impacted the latent proviruses. Our results 
demonstrated that it effectively reactivated viral transcription 
and replication not only in J-Lat HIV latency cell line but in 
primary CD4+ T cells from chronically SIV-infected macaques 
and HIV-infected patients. Arsenic trioxide is able to regulate 
multiple transcriptional signaling factors, including NF-kB, 
protein kinase C, PML-NB, etc., and these signaling pathways 
are actually associated with the reactivation by other LRAs such 
as bryostatin-1 and SAHA.[30–32] Notably, this reactivation by 
arsenic trioxide treatment was not accompanied by significantly 
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Figure 5. Arsenic trioxide downregulated the expression of CD4 and CCR5 on CD4+ T cells and reduced susceptibility to spread SIV infection. Primary 
CD4+ T cells isolated from SIV-infected or SIV-negative healthy macaques were treated with arsenic trioxide for 5 days and then assessed using flow 
cytometry. A) the proportion of CD4+ T cells; B) the median fluorescent intensity (MFI) of CD4 expression; C) expression level of CCR5 on the surface 
of CD4+ T cells. Sorted CD4+ T cells from SIV-infected macaques were incubated with arsenic trioxide for 72 h, and the D) intracellular viral RNA 
copies, E) intracellular viral DNA copies, and F) viral RNA copies in the culture media of primary CD4+ T cells were determined by RT-qPCR. The final 
data were represented as the means ± standard deviations of triplicate experiments. *p < 0.05, **p < 0.01, ***p < 0.001.
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devastating T cell activation and proinflammatory responses 
(Figures 2 and 3). Despite the underlying mechanisms remain 
to be determined, the characteristic of arsenic trioxide is supe-
rior to other LRAs. Nevertheless, the ultimate answer should 
come from future clinical studies in HIV-infected patients.
Intriguingly, we found that arsenic trioxide downregulated 
cell surface expression of CD4 and CCR5, which are the key 
receptors and coreceptors to mediate HIV-1/SIV attachment 
and entry into target cells. It is worth noting that the two suc-
cessful cases of HIV cure (Berlin patient and London patient) 
are attributed to the use of CCR5-△32 mutant bone marrow 
transplants,[33,34] which illustrated the importance of CCR5 
receptor in controlling HIV infection. Our current research, 
downregulating CCR5 expression in vitro (Figure 5) and in 
SIV-infected macaques (Figure 6) by arsenic trioxide treat-
ment, shares somehow analogical characteristic with these 
two encouraging examples. Thus, arsenic trioxide may prevent 
the spread of viral infection to bystander CD4+ T cells. How-
ever, it is unclear to what degree the downregulation of CD4 
and CCR5 contributes to the regulation of viral infection in 
the presence of arsenic trioxide and ART. Interestingly, recent 
studies demonstrated that some potential LRAs, such as Bry-
ostatin-1, PEP005, and diterpene analogs were capable of 
reducing the HIV receptors and coreceptors CD4, CCR5, and 
CXCR4 expression and the susceptibility of naive CD4+ T cells 
to HIV-1 acquisition.[35–37] The mechanisms of downregulating 
the HIV receptor/coreceptor by some LRAs remain to be inves-
tigated. However, these results suggest that a novel strategy 
for functionally curing HIV infection might be developed by 
reducing or inhibiting the expression of CCR5 receptor on the 
surface of CD4+ cells by drug treatment.
Based on our observation, we proposed that the antigen-
specific immune responses should ideally be improved 
simultaneously when an LRA is used in order to effectively 
eliminate those activated viruses. The importance of antigen-
specific immune responses in controlling HIV/SIV infection 
has been extensively emphasized by many studies.[38–41] For 
example, off-therapy remission of SIV viremia after ART dis-
continuation was observed when SIV-infected Indian rhesus 
macaques were treated using buthionine sulfoximine in 
combination with auranofin, and this control was correlated 
with the enhanced antigen-specific CD8+ T cells.[42] To some 
extent, the mechanism of arsenic trioxide controlling viral 
rebound in this study is similar to that of above drugs. That is, 
SIV-specific immune responses were significantly increased 
by arsenic trioxide treatment, which play important role in 
eliminating the infected cells harboring latent SIV during the 
viral reactivation. The enhancement of SIV-specific immune 
responses by arsenic trioxide treatment, therefore, contributed 
to suppressing viral rebound in chronic SIV-infected rhesus 
macaques.
Our study has limitations. This is a pilot study of relatively 
small numbers of macaques, and only four animals per group 
were used in this study. Future studies with a larger number of 
macaques, in both acute and chronic infection models, should 
be performed with arsenic trioxide in combination with ART. 
Adv. Sci. 2019, 1900319
Figure 6. Enhanced SIV specific T cell immune responses after administration of arsenic trioxide in combination with ART in chronic SIV-infected 
rhesus macaques. Specific T cell immune responses against the SIVmac239 Gag, Pol, and Env antigens were monitored by IFN-γ-mediated ELISPOTs 
at different time points: A) before ART in combination with arsenic trioxide therapy; B) after ART in combination with arsenic trioxide therapy. C) Statis-
tical analysis of the ELISPOT data before and after arsenic trioxide treatment. D) Effect on T cell activation markers, including CCR5, CD95, and CD69 
after administration of arsenic trioxide four weeks in SIV-infected macaques. SFC, spot forming cells. The final data were represented as the means ± 
standard deviations of triplicate experiments. *p < 0.05, **p < 0.01.
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Although the number of macaques was relatively limited, these 
eight macaques were distributed very carefully based on age, 
sex, weight, and genotype. All SIV-infected macaques used in 
this study had a long history of SIV infection and had several 
courses of ART therapy, which mimics treatment of chronic 
HIV-1 infection in humans. These macaques were infected 
with SIVmac239 for more than 5 years, and the viral load in 
plasma ranged from 3.60 to 6.33 log when starting this study 
(Table S1, Supporting Information). Highly pathogenic SIV-
infected macaques have been well-validated as a stringent 
model to recapitulate HIV-1 pathogenesis and persistence 
during ART therapy in humans.[43] Indeed, in our Chinese 
rhesus model, ART treatment effectively suppressed SIV infec-
tion to undetectable levels in plasma, and upon ART discontinu-
ation, virus rapidly rebounded, which is very similar with that 
in ART-treated HIV patients. Previous studies showed that SIV 
pathogenesis in Chinese-origin macaques resembled HIV-1 
infections in adult humans more closely, compared with that 
in Indian-origin macaques.[43–45] Although arsenic trioxide in 
combination with ART demonstrated a promising result in 
our animal model, future studies are needed to test if repeated 
courses of arsenic trioxide with ART might progressively 
deplete latent viral reservoir.
Taken together, our study demonstrate that arsenic trioxide 
effectively reactivates viral latency and delays viral rebound after 
termination of ART in chronically SIV-infected rhesus macaques. 
The mechanism may involve with multiple modes acting syn-
ergistically. Arsenic trioxide inhibits the spread of released SIV 
due to reactivation of latent SIV provirus by downregulating the 
expression of CD4 receptors and CCR5 coreceptors of host cells, 
which reduce susceptibility of virus to attach and enter CD4+ T 
cells. Furthermore, suppression of SIV infection and replication 
can be enhanced by the restored SIV specific immune responses. 
Since arsenic trioxide formulation is commercially available and 
being approved as a drug for the treatment of malignancies in 
humans, further studies should consider combining arsenic tri-
oxide with ART in HIV-1-infected patients.
Experimental Section
Drugs and SIV Peptide Pools: Arsenic trioxide (Beijing ShuangLu 
Pharmaceutical Co., Ltd., China) was a clinically available drug for 
treatment of APL and advanced HCC, which was issued by China Food 
and Drug Administration (approval number: H20080665).
Reverse Transcriptase Inhibitors: PMPA (also called tenofovir) and 
FTC (also called emtricitabine) were provided by Shanghai Desano 
Pharmaceutical Co., Ltd. Those drugs were provided in powder 
formation of active pharmaceutical ingredient, and dissolved in 0.9% 
saline solution to a final concentration as below.
Peptide pools, which covered the entire SIVmac239 sequences of 
Gag, Pol, Env, Nef, Vif, Vpx, Vpr, Rev, and Tat proteins, were obtained 
through the AIDS Research and Reference Reagent Program, National 
Institutes of Health (NIH), USA. Peptide pools consisted of 15 amino 
acids shifted by 11 overlapping amino acids residues, and dissolved in 
dimethyl sulfoxide to a final concentration of 0.4 mg per peptide mL−1 
before use.
CD4+ T Cell Sorting, Reactivation, RNA Extraction, and Nested 
Real-Time Polymerase Chain Reaction (PCR) Assay for Cell-Associated 
RNA Detection: PBMCs from HIV-infected subjects or SIV-infected 
macaques were isolated by standard Ficoll-Hypaque density gradient 
centrifugation. CD4+ T cells were sorted using a human CD4+ T cell 
isolation kit or nonhuman primate CD4+ T cell isolation kit (Miltenyi 
Biotec), following the standard magnetic cell sorting protocol. The 
purified CD4+ T cells were counted and suspended in 200 µL of 
medium (Roswell Park Memorial Institute (RPMI) 1640 with 10% 
fetal bovine serum (FBS) and 1% penicillin/streptomycin) in 96-well 
U-bottom plate. Each well had 0.5 to 2 million of CD4+ T cells. After 
24 h stimulation with different compounds, cell-associated RNA was 
extracted according to the manufacturer’s protocol (Qiagen, RNeasy 
Mini Kit), and eluted into 30 µL of RNase-free water. Aliquots of 15 µL 
RNA were directly reverse-transcribed following the standard procedure 
(BIO-RAD, transcription supermix for reverse transcription-quantitative 
real-time PCR (RT-qPCR)). For nested real-time PCR, cell-associated 
complementary DNA (cDNA) or serial dilutions of cDNA standards was 
subjected to two rounds of PCR amplification.
Two kinds of cell-associated RNA were detected, including msRNA 
(multiply spliced transcripts of HIV/SIV) and usRNA (unspliced transcripts 
of HIV/SIV). For detection of msRNA, three primers crossing Tat and Rev 
for seminested real-time PCR were designed, because of the sequence 
specificity of the detection region. The first round of msRNA PCR was 
performed with the primer msRNA-1F and msRNA-R, and the second-
round real-time PCR was performed with the primer pair msRNA-2F and 
msRNA-R. Either Taqman probes or SYBR Green were used for msRNA 
detection at the second-round real-time PCR, and the amplicon sizes 
were 130 bp for the first-round PCR and 103 bp for the second-round real-
time PCR. For detection of usRNA, two pairs of primers were designed to 
amplify a region within the HIV-1/SIV gag gene. The primer pair U1-5F 
and U1-3R was used in the first-round PCR and the amplicon size was 
227 bp. The primer pair U2-5F and U2-3R was used in the second-round 
PCR, and the amplicon size was 176 bp. All primer sequences used in this 
study were listed in Table S3, Supporting Information.
Quantitative PCR Analysis of Cytokines: PBMCs from healthy or SIV-
infected macaques were isolated using Ficoll-Hypaque solution, and 
incubated with arsenic trioxide overnight. The total RNA was extracted 
from cultured cells using a RNA easy Mini Kit (Qiagen) and reverse-
transcribed with iScript cDNA synthesis kit (Bio-Radioquantitative PCR 
was performed with a QuantiFast SYBR Green PCR Kit (Qiagen) in the 
CFX-96 Real-time PCR system (Bio-Rad). β-macroglobulin RNA was 
used as the internal control. A cocktail of PMA and ionomycin was used 
as a positive control for T cell activation. All primer sequences used in 
this study were listed in Table S3, Supporting Information.
Animals and Treatment: Chinese rhesus monkeys (Macaca mulatta) 
were housed in the Experimental Animal Center of Guangzhou Institutes 
of Biomedicine and Health (GIBH, Guangzhou, China). The use of 
animals in this study was approved by our Institutional Animal Care and 
Use Committee. All monkeys in this study were chronically infected with 
SIVmac239 and assigned into two groups based on comparable viral load, 
weight, and sex (Table S1, Supporting Information). They received the 
following antiretroviral therapy for 12 weeks: 30 mg kg−1 PMPA and 20 mg 
kg−1 FTC, both injected subcutaneously once daily. During ART treatment, 
four monkeys received 0.16 mg kg−1 arsenic trioxide in 0.9% saline through 
intravenous infusion once daily for four weeks. Another group of four 
monkeys were used as controls with mock treatment. They received the 
same volume of saline through intravenous infusion once daily for four 
weeks.
Immunological Assays: Immunological assays included the ELISPOT 
assay, intracellular cytokine staining (ICS) for polyfunctionality of 
T lymphocytes and CFSE staining for cell proliferation; these were 
performed as described previously.[27,38] Multicolor ICS assays and 
phenotypic markers of T lymphocyte population were performed 
with the following monoclonal antibodies: anti-CD3-Pacific Blue, 
anti-CD4-AmCyan, anti-CD8-allophycocyanin (APC)-Cy7, anti-CD28-
fluorescein isothiocyanate (FITC), anti-CD95-phycoerythrin (PE)-Cy5, 
anti-IFN-PE, anti-TNF-α-PE-Cy7, and anti-IL-2-APC (BD Pharmingen). 
Samples were analyzed with a FACSAria flow cytometer (BD Biosciences) 
and FlowJo software (version 7.6; Tree Star, Inc.). The number of 
circulating CD4+ T lymphocytes was determined using BD TruCount 
tubes according to the manufacturer’s instructions (BD Biosciences). 
Activation markers were detected with the following monoclonal 
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antibodies: anti-CD3-PerCP, anti-CD4-FITC, anti-CD4-APC, anti-CD38-
FITC, anti-CD25-APC, anti-CD69-PE, anti-CD95-PE-Cy5, anti-Ki67-PE, 
anti-CCR5-PE. Samples were analyzed with a Accuri C6 flow cytometer 
(BD Biosciences) and FlowJo software (version 7.6; Tree Star, Inc.).
Viral Load Determination by Real-Time PCR: Levels of plasma SIV 
RNA were quantitated by real-time PCR as described previously.[27,38] 
Briefly, viral RNA was isolated from plasma using the QIAamp Viral 
RNA Minikit (Qiagen) and amplified using the QuantiTect SYBR Green 
RT-PCR Kit (Qiagen). Primers were designed to match the SIVmac239 
gag sequence. The copy number of viral RNA was calculated based on 
the standard curve of an in vitro-transcribed fragment of the SIVmac239 
gag gene. The limitation for this assay was 100 copies mL−1 plasma.
Viral DNA Assays: Levels of integrated SIVmac239 DNA in PBMCs 
were quantitated using Alu-PCR method, as previously described.[38,46] 
Briefly, PBMCs from the macaques were isolated by standard Ficoll-
Hypaque density gradient centrifugation, and CD4+ T cells were purified 
using a nonhuman primate CD4+ T cell isolation kit (MiltenyiBiotec), 
following the standard magnetic cell sorting protocol. The purified CD4+ 
T cells were counted, and total cellular DNA was isolated from 5 × 106 
cells using a QIAamp DNA Blood Mini kit (Qiagen). The integrated 
SIVmac239 DNA was determined by nested PCR with two pairs of 
primers. A mix with SIVgag-reverse primer and Alu-forward primer 
were used in the first round of PCR, and a pair of primers specific to a 
conserved region of SIVgag gene was used in the second round of PCR. 
Quantification was analyzed by comparing with an integration standard 
of CEMss/pWPXLD-rc cell genome. PCR assays were performed with 
100–500 ng samples of DNA.
Quantitation of Circulating CD4+ T Lymphocytes: The number of 
circulating CD3+, CD4+, and CD8+ T lymphocytes were determined 
using BD TruCount tubes according to the manufacturer’s instructions 
(BD Biosciences).
Statistics: Flow cytometry software analysis was performed using 
FlowJo 7.6 (Tree Star Inc.). Graphical representations were generated 
with GraphPad Prism 5.01 (GraphPad Software Inc., La Jolla, CA). Two-
tailed p values were calculated for all analyses, and differences were 
considered statistically significant when p values were less than 0.05.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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